Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences, Inc. reported third-quarter 2026 revenue of $9 million versus $26 million a year earlier and net loss of $128 million versus $135 million. In the first nine months, revenue was $67 million versus $214 million and net loss was $347 million versus $247 million. Lower collaboration revenue included the absence of a $143 million 2025 cumulative catch-up after Gilead terminated its etrumadenant rights.
As of September 30, 2026, Arcus had $694 million in cash, cash equivalents and marketable securities. In October 2026, it sold 16.4 million shares at $17.50 per share for approximately $288 million in gross proceeds. Arcus said it believed September liquidity plus the October financing would be sufficient for planned operations into 2029. Gilead's access to the broader R&D pipeline ended July 14, 2026, after it declined the $100 million sixth-anniversary continuation payment; it retained time-limited options to AXL, CD39 and TNF programs and an oncology research program.
October 2026 ARC-20 data, with a September 4, 2026 cutoff, included median progression-free survival of 14.5 months for second-line casdatifan plus cabozantinib (43 patients; 21.3 months' median follow-up). Arcus also announced that Phase 3 PACIFIC-8, testing domvanalimab plus durvalumab versus durvalumab alone in Stage III unresectable NSCLC, was discontinued in August 2026.
Arcus Biosciences, Inc. reported third-quarter 2026 results and clinical updates. Revenue was $9 million, versus $26 million a year earlier, and net loss was $128 million, versus $135 million. Research and development expense was $117 million, compared with $141 million; general and administrative expense was $23 million, versus $27 million.
Cash, cash equivalents and marketable securities were $694 million as of September 30, 2026; Arcus also reported $288 million gross proceeds from its October equity financing and believes these resources will fund its planned level of operations into 2029. Arcus expects full-year 2026 GAAP revenue of $70 million to $75 million. In ARC-20's first-line cohort (30 patients; 11.5 months median follow-up), casdatifan plus zimberelimab showed a 50% cORR and landmark PFS of 86% at 6 months and 69% at 12 months. Late-line casdatifan monotherapy showed median OS of 35 months. These molecules are investigational; approval has not been received, and safety and efficacy have not been established.
PEAK-1 enrollment is expected to be complete in the next two to three months, PEAK-20 is expected to initiate in the fourth quarter of 2026, and additional ARC-20 data are expected in 2027.
Arcus Biosciences, Inc. (RCUS) completed a public offering and issuance of 16,428,572 shares of common stock on October 23, 2026, including the full exercise of the underwriters’ option. The public offering price was $17.50 per share. The offering included 14,285,715 initial shares and an option for up to 2,142,857 additional shares, exercisable for 30 days from the October 21, 2026 underwriting agreement.
The underwriters agreed to purchase the shares from Arcus at $16.45 per share. Arcus received approximately $269.7 million in net proceeds after underwriting discounts and commissions and estimated offering expenses payable by the company. The offering was made under an effective Form S-3 registration statement and accompanying prospectus supplements.
Arcus Biosciences, Inc. (RCUS) is offering 14,285,715 shares of common stock at $17.50 per share, with estimated net proceeds of approximately $234.5 million after underwriting discounts and estimated expenses. The underwriters may purchase up to 2,142,857 additional shares under an option exercisable for 30 days from the prospectus supplement date; full exercise would bring estimated net proceeds to approximately $269.7 million.
Arcus plans to use the proceeds for ongoing research and development, including expanding and accelerating clinical development of casdatifan, and for working capital, operating expenses and other general corporate purposes. The company estimated approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026; this preliminary unaudited estimate is subject to completion of closing procedures and management review.
The prospectus states immediate net tangible book value dilution to new investors of $12.56 per share, or $12.39 per share if the underwriters exercise their option in full. Arcus had 127,018,631 shares of common stock outstanding as of June 30, 2026.
Arcus Biosciences, Inc. proposes a primary offering of common stock under its shelf registration, with proceeds payable to the company. The preliminary prospectus supplement is subject to completion.
Arcus Biosciences, Inc. (RCUS) estimated that it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The preliminary, unaudited estimate is based on information available to management as of October 21, 2026, and remains subject to completion of financial closing procedures, including management reviews; it may differ from the actual September 30 balance. Ernst & Young LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to the preliminary data and expressed no opinion or other form of assurance on it.
Arcus Biosciences, Inc. (RCUS) presented ARC-20 platform study data on casdatifan in clear cell renal cell carcinoma (ccRCC), covering first-line combinations, a second-line combination and late-line monotherapy. Data cutoff was September 4, 2026.
With first-line casdatifan plus zimberelimab (n=30), median follow-up was 11.5 months; confirmed objective response rate (cORR) was 50%, and landmark progression-free survival (PFS) was 86% at six months and 69% at 12 months. With casdatifan, ipilimumab and zimberelimab, one of 24 patients reaching a first scan had primary progression after three months of median follow-up; no unexpected safety signals were observed among 31 patients who received at least one dose.
In the second-line casdatifan plus cabozantinib cohort (n=43), after 21.3 months of median follow-up, median PFS was 14.5 months, 18-month landmark overall survival was 77%, cORR was 44%, and primary progression was 5%. Across four pooled late-line monotherapy cohorts (n=121), after 28 months of median follow-up, median overall survival was 35 months, median PFS was 13 months, and cORR was 36%. Monotherapy adverse events were described as acceptable and manageable.
Arcus Biosciences, Inc. (RCUS) reported that Chief Accounting Officer Alexander Azoy exercised a stock option for 2,827 shares of common stock at an exercise price of $15.44 per share and on the same date sold 2,827 shares at $30.00 per share. After the option exercise, Azoy holds 3,073 stock options directly, with the option expiring on January 22, 2034. The option exercises and related sale were effected under a Rule 10b5-1 trading plan.
Arcus Biosciences, Inc. (RCUS) is the issuer for a Rule 144 notice filed for the planned sale of its common stock by officer Alexander Azoy. The filing lists 2,827 shares of common stock, with an aggregate market value of $83,453.04, to be sold through Morgan Stanley Smith Barney LLC, with the shares to be issued upon the exercise of stock options for cash. The notice also references prior 10b5-1 plan sales of 2,562 shares for $66,023.76 on June 1, 2026.
Gilead Sciences, Inc. reports its beneficial ownership in Arcus Biosciences, Inc. common stock in Amendment No. 7 to its Schedule 13D. Gilead holds 31,424,760 shares of common stock, representing 24.7% of the 127,333,376 shares outstanding reported in Arcus’s most recent quarterly report.
This position reflects multiple equity purchases: 2,200,000 shares in a 2020 public offering, several tranches under successive stock purchase agreements, a 15,238,095‑share purchase at $21.00 per share in 2024, and 1,363,636 shares in a 2025 public offering, all funded with cash. The stake is tied to an Option, License and Collaboration Agreement that gives Gilead an exclusive option to licenses on Arcus programs over a 10‑year term plus up to three additional years for certain programs, and to updated equity and investor rights agreements that include lock-up provisions and registration rights. A prior option allowing Gilead to increase its stake to as much as 35% expired on July 13, 2025. Gilead states it currently has no specific plans for major corporate actions but may review its investment and engage with Arcus over time. Director Jeffrey A. Bluestone beneficially owns options on 13,563 shares, or 0.01% of Arcus.